|10 June 2010
New Journal Studies
AAO Online Community (AAO Members)
NEW JOURNAL STUDIES
Vitamin E does not decrease AMD risk
Data from the Women's Health Study, a large, randomized, controlled trial evaluating the effects of vitamin E and low-dose aspirin among healthy women shows that that 10 years of alternate-day treatment with 600 IU of natural source vitamin E alone has no material beneficial or harmful effect on the occurrence of AMD. Participants were assigned to take vitamin E or placebo on alternate days. It also found that vitamin E had no significant effect on the secondary endpoints of advanced AMD and total AMD with or without vision loss. Ophthalmology, June 2010
Intracameral voriconazole appears effective against fungal endophthalmitis resulting from keratitis
This retrospective study evaluated outcomes in 10 eyes with fungal endophthalmitis resulting from keratitis treated with an intracameral injection of 100 μg voriconazole. In all cases, regardless of ultimate outcome, clinical appearance of the fungal anterior chamber invasion, including hypopyon, fungal web, fungal ball, and endothelial plaque, resolved after treatment. Of the seven patients who had five or more repeat injections, six were caused by Fusarium and one by Acremonium. In the other three patients who had four or fewer injections, the causative organisms were Aspergillus and Alternaria. American Journal of Ophthalmology, June 2010
More evidence suggesting dexamethasone implant effectively treats BRVO, CRVO
This multicenter, masked, randomized trial included 1267 patients treated with either a sham procedure or with 0.35 or 0.7 mg dexamethasone implant. All patients had vision loss due to macular edema associated with branch retinal vein occlusion or central retinal vein occlusion. At six months, both treated groups achieved significantly greater improvements in visual acuity than did the sham group. The gains in visual acuity were accompanied by greater decreases in OCT-measured central retinal thickness compared to the sham group. Ophthalmology, June 2010
Bevacizumab improves macular function in patients with myopic choroidal neovascularization
This prospective case series included 15 eyes with subfoveal choroidal neovascularization secondary to myopic choroidal neovascularization treated with one intravitreal injection of 1.25 mg bevacizumab. At 12 months patients showed significantly improved macular function as evidenced by increased BCVA and mean retinal sensitivity, improved fixation stability, and reduced central absolute scotoma area. A single injection was enough to halt CNV in most patients. Mean injection rate was 1.53. Retina, May 2010
Anti-VEGF therapy appears effective in patients with pseudoxanthoma elasticum
This case series included nine eyes with pseudoxanthoma elasticum and choroidal neovascularization treated with either bevacizumab 1.25 mg/0.05 mL or ranibizumab 0.5 mg/0.05 mL. During a mean follow-up period of 28.6 months, visual acuity either improved or stabilized in all nine eyes. Mean visual acuity improved from 20/368 to 20/281. Serial optical coherence tomography measurements showed mean lesion height decreased from 353 µm at baseline to 146 µm at the last visit (P =0.005). Patients received an average of 8.4 injections. No complications were noted. Retina, May 2010
Ectasia Risk Score System may not accurately predict post-LASIK ectasia in eyes with normal topography
This retrospective analysis included data from 1702 myopic eyes with normal topography that underwent LASIK by one surgeon between 1995 and 2008. None of the 92 eyes (5.4 percent) identified by the Randleman Ectasia Risk Score System as being too high-risk for LASIK developed ectasia, nor did the additional 6.8 percent identified as “moderate risk”. However, three eyes with preoperative topographic keratoconus and no other risk factors taken from the same surgeon’s database did develop ectasia. Journal of Refractive Surgery, April 2010
Back to Top
Get real-time event information with the Joint Meeting Program Search
Search the 2010 Joint Meeting by presenter, topic, special interest or event type. Login to the Program Search to build your personalized schedule using the calendar feature. When registration opens, purchase tickets for the events saved in your calendar.
New on the ONE Network: How to use the modified capsular tension ring for severe zonular damage (AAO members)
Robert J. Cionni, MD, provides an overview and video demonstration of how to use the Morcher CTR in patients with severe zonular damage.
Study with the experts – online
Maintenance of Certification (MOC) Exam Review Course Presentations are adapted from the live didactic sessions of the MOC Exam Review Course™ and cover Core Ophthalmic Knowledge material for eight practice emphasis areas (PEAs). Available online, each presentation is led by experts who created the Practicing Ophthalmologists Curriculum (POC), on which the DOCK is based. Visit the ONE Network for a full list of PEAs, presenters and topics. Each presentation $49 member / $65 nonmember.
What has the Academy been up to? Where are we headed?
Find out what the Academy is delivering to members and what it means for you – from cutting-edge initiatives to big plans for this year and beyond. Our first-ever Year in Review report gives you a quick rundown of topics including our position on health care reform, improved learning tools on the ONE Network, the new EyeWiki , better eye health information for patients on the Web and much more.
Back to Top
AAO ONLINE COMMUNITY (AAO MEMBERS)
What’s new in the Academy online community
Browse all community groups in our new listing of all subspecialty and alumni groups and more. To get even more highlights from the community each week, sign up for our weekly e-mail newsletter, Community Connection. Access all of our featured content on the “What’s New” page on the community.
Back to Top